Intravenous immunoglobulins and haematopoietic growth factors in the prevention and treatment of neonatal sepsis: Ground reality or glorified myths?

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 482-487

  Shaw, Chandan Kumar ^a,b   Thapalial, A ^a   Shaw, P ^a   Malla, K ^a  

^a MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

^b MANIPAL TEACHING HOSPITAL   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON ANTIBODY; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; BONE MARROW; CELL PROTECTION; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; NEUTROPHIL CHEMOTAXIS; NEWBORN HEMOLYTIC DISEASE; NEWBORN SEPSIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VERY LOW BIRTH WEIGHT;

DEVELOPING COUNTRIES; FEASIBILITY STUDIES; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; SEPSIS;

EID: 33847039968     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01162.x     Document Type: Review

References (44)

1. National Neonatology Forum. National Neonatology Database: report. Indian Pediatr 1989; 36: 167-9.
2. Stoll BJ. Infections of the neonatal infant. In: Behrman RE, Kleigman RM, Jenson HB, eds. Nelson Textbook of Pediatrics, 17th edn. Philadelphia, PA: Saunders, 2004; pp. 623-40.
3. Stoll BJ. The global impact of neonatal infection. Clin Perinatol 1997; 24: 1-21.
4. Paul VK, Ramani AV. Newborn care at peripheral health facilities. Indian J Pediatr 2000; 67: 378-82.
5. Mohan PV, Tarnow-Mordi W, Stenson B et al. Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants? Arch Dis Child Fetal Neonatal Ed 2004; 89: F5.
6. Baker CJ. New uses of intravenous immune globulin in newborn infants. J Clin Immunol 1990; 10 (Suppl. 6): 47S-52 (discussion; 52S-5S).
7. Cairo MS. Pathophysiology and clinical aspects of neonatal immunology. In: Pomerance JJ, Richardson CJ, eds. Neonatology for the Clinician. Norwalk, CT: Appleton & Lange, 1993; pp. 201-10.
8. Andersson J, Skansen-Saphir U, Sparrelid E et al. Intravenous immunoglobulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl. 1): 10-20.
9. Aukrust P, Muller F, Svenson M et al. Administration of intravenous immunoglobulin (IVIG) in vivo downregulatory effects of the IL-1 system. Clin Exp Immunol 1999; 115: 136-43.
10. Ross C, Svenson M, Hansen MB et al. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995; 95: 1974-8.
11. Stangel M, Schumacher HC, Ruprecht K et al. Immunoglobulins for intravenous use inhibit TNF-α cytotoxicity in vitro. Immunol Invest 1997; 26: 569-78.
12. + dependent signal transduction through Fcg receptors on B lymphocytes. Scand J Immunol 1994; 40: 37-42.
13. Kaveri S, Vassilev T, Hurez V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97: 865-9.
14. Teeling JL, De Groot ER, Eerenberg AJM et al. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998; 114: 264-70.
15. Lutz HU, Stammler P, Jelezarova E et al. High doses of immunoglobulin G attenuate aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88: 184-93.
16. Molloy EJ, O'Neill AJ, Grantham JJ et al. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor have differential effects on neonatal and adult neutrophil survival and function. Pediatr Res 2005; 57: 806-12 (Epub 2005 Feb 17).
17. Maianski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW. Granulocyte colony-stimulating factor inhibits the mitochondriadependent activation of caspase-3 in neutrophils. Blood 2002; 99: 672-9.
18. Tehranchi R, Fadeel B, Forsblom AM et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 1080-6.
19. Maianski NA, Roos D, Kuijpers TW. Bid truncation, bid/bax targeting to the mitochondria, and caspase activation associated with neutrophil apoptosis are inhibited by granulocyte colony-stimulating factor. J Immunol 2004; 172: 7024-30.
20. Wolach B, Gavrieli R, Pomeranz A. Effect of granulocyte and granulocyte macrophage colony stimulating factors (G-CSF and GMCSF) on neonatal neutrophil functions. Pediatr Res 2000; 48: 369-73.
21. Ohls RK, Bellis YM, Dupree JC, Sklar LC. Effects of granulocyte colony-stimulating factor on neutrophil adhesive molecules in neonates. J Pediatr Hematol Oncol 2001; 23: 506-10.
22. Gessler P, Neu S, Nebe T, Speer CP. Granulocyte colony-stimulating factor receptor expression on neutrophils of term and preterm neonates with and without signs of infection. Eur J Pediatr 1999; 158: 497-500.
23. Cairo MS, Suen Y, Knoppel E, van de Ven C, Nguyen A, Sender L. Decreased stimulated GM-CSF production and GM-CSF gene expression but normal numbers of GM-CSF receptors in human term newborns compared with adults. Pediatr Res 1991; 30: 362-7.
24. Shimada M, Minato M, Takada M, Takahashi S, Harada K. Plasma concentration of granulocyte-colony-stimulating factor in neonates. Acta Paediatr 1996; 85: 351-5.
25. Kantar M, Kultursay N, Kutukculer N, Akisu M, Cetingul N, Caglayan S. Plasma concentrations of granulocyte-macrophage colony-stimulating factor and interleukin-6 in septic and healthy preterms. Eur J Pediatr 2000; 159: 156-7.
26. Plasma Exchange/Sandoglobulin Gullian-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barre syndrome. Lancet 1997; 349: 225-30.
27. Hahn F, Bolton CF, Zochodne D et al. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled, cross-over study. Brain 1996; 119: 1067-77.
28. Van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59: 248-52.
29. Clegg A, Bryant J, Milne R. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000; 4: 1-101.
30. Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402.
31. Fazekas F, Deisenhammer F, Strasser Fuchs S et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93.
32. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2004; (1): CD001239.
33. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immunoglobulin for prevention and treatment of neonatal sepsis. Pediatrics 1997; 99: 2/e2.
34. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev 2004; (1): CD000361.
35. Bedford Russell AR, Emmerson AJ, Wilkinson N et al. A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birth weight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2001; 84: F172-6.
36. Gillan ER, Christensen R, Suen Y et al. A randomized, placebocontrolled trial of recombinant human granulocyte-colony stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994; 84: 1427-33.
37. Miura E, Procianoy RS, Bittar C et al. A randomized, doublemasked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-35.
38. Kucukoduk S, Sezer T, Yildiran A, Albayrak D. Randomized, double-blinded, placebo-controlled trial of early administration of recombinant human granulocyte colony-stimulating factor to nonneutropenic preterm newborns between 33 and 36 weeks with presumed sepsis. Scand J Infect Dis 2002; 34: 893-7.
39. Cairo MS, Christensen R, Sender LS et al. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets and bone marrow neutrophils. Blood 1995; 86: 2509-15.
40. Cairo MS, Agosti JM, Ellis R. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte- macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. J Pediatr 1999; 134: 64-70.
41. Carr R, Modi N, Dore CJ et al. A randomized, controlled trial of prophylactic granulocyte-macrophage colony-stimulating factor in human newborns less than 32 weeks gestation. Pediatrics 1999; 103 (pt 1): 796-802.
42. Bilgin K, Yaramis A, Haspolat K et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36-41.
43. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003; (3): CD003066.
44. Ahmad A, Laborada G, Bussel J, Nesin M. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte macrophage colony-stimulating factor and placebo for treatment of septic preterm infants. Pediatr Infect Dis J 2002; 21: 1061-5.